TY - JOUR
T1 - Sodium oxybate in the treatment of alcohol withdrawal syndrome: a randomized double-blind comparative study versus oxazepam. The GATE 1 trial
AU - Caputo, F
AU - Skala, K
AU - Mirijello, A
AU - Ferrulli, A
AU - Walter, H
AU - Lesch, O
AU - Addolorato, Giovanni
PY - 2014
Y1 - 2014
N2 - Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. The aim of this phase IV, multicenter, randomized, double-blind, double-dummy study was to evaluate the efficacy of SMO in comparison with oxazepam in the treatment of uncomplicated AWS.
AB - Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. The aim of this phase IV, multicenter, randomized, double-blind, double-dummy study was to evaluate the efficacy of SMO in comparison with oxazepam in the treatment of uncomplicated AWS.
KW - alcohol withdrawal syndrome
KW - sodium oxybate
KW - alcohol withdrawal syndrome
KW - sodium oxybate
UR - https://publicatt.unicatt.it/handle/10807/60505
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84905560288&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84905560288&origin=inward
U2 - 10.1007/s40263-014-0183-1
DO - 10.1007/s40263-014-0183-1
M3 - Article
SN - 1172-7047
VL - 28
SP - 743
EP - 752
JO - CNS Drugs
JF - CNS Drugs
IS - 8
ER -